Context Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
CNTX$0.20+3.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Year ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating expenses: | ||
| Research and development | $31,856,252 | $22,701,335 |
| General and administrative | 7,846,379 | 7,222,565 |
| Loss from operations | (39,702,631) | (29,923,900) |
| Interest income | 3,378,545 | 3,200,224 |
| Other income (expense) | 200,471 | (1,428) |
| Net loss | $(36,123,615) | $(26,725,104) |
| Net loss per common share, basic and diluted | $(0.38) | $(0.46) |
| Weighted average shares outstanding, basic and diluted | 95,185,683 | 58,416,141 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.